Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on March 29, 2021 a capital increase of 200,000 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 50,123,200.33 EUR and is represented by 14,405,156 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 29 March 2021 following the Capital Increase.
| Total amount of share capital (EUR) | 50,123,200.33 |
| Total Number of shares with single voting rights | 14,332,832 |
| Total Number of shares with double voting rights | 72,324 |
| Total Number of Shares | 14,405,156 |
| Total of voting rights | 14,477,480 |
| Total number of attributed warrants | 1,734,439 |
| Total number of shares with voting rights that could be created following the exercise of the attributed warrants | 1,734,439 |
| Total number of diluted shares (Outstanding shares + Warrants) | 16,139,595 |
| Total number of diluted shares with voting rights | 16,211,919 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
Further questions about the content of this release can be sent to investors@celyad.com.
